Infect Chemother.  2012 Oct;44(5):399-402. 10.3947/ic.2012.44.5.399.

The First Case of Abacavir Hypersensitivity Associated with the HLA-B*57:01-Positive Allele in Korea

• Yoon JH
• Kim M
• Jin SJ
• Kim SK
• Lee SH
• Cheon J
• Yun GY
• Kim MK
• Ha J
• Song YG

• KMID: 2170388
• DOI: http://doi.org/10.3947/ic.2012.44.5.399

Abstract

On the 12th day of abacavir treatment, a 39-year old HIV-infected male patient was admitted with fever, generalized rash, abdominal pain, and watery diarrhea that had persisted for five days. Results of blood tests indicated rapid progression of hepatitis and renal failure. The day after stopping anti-retroviral therapy, his fever subsided and his liver function began to normalize. He was clinically diagnosed with abacavir hypersensitivity and was found to carry the HLA-B*57:01 allele. This is the first reported case of abacavir hypersensitivity associated with the presence of the HLA-B*57:01 allele in Korea.

Keyword

Abacavir; Hpersensitivity; HLA-B*57:01; Korea

MeSH Terms

Abdominal Pain
Alleles
Diarrhea
Dideoxynucleosides
Exanthema
Fever
Hematologic Tests
Hepatitis
Humans
Hypersensitivity
Korea
Liver
Male
Renal Insufficiency
Dideoxynucleosides

Figure

• 

  Figure 1 (A, B) Computer tomographic images of the abdomen show hepatic congestion, mild splenomegaly, and gallbladder edema. (C, D) Computer tomograpic images of the chest show normal lung parenchyme and small axillar lymph nodes.

Reference

1. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H. Hypersenstivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001. 23:1603–1614.

2. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR-7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002. 359:727–732.

3. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008. 358:568–579.

4. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M. Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008. 46:1111–1118.

5. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002. 16:2223–2225.

6. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002. 359:1121–1122.

7. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD. CNA30027 Study Team. CNA30032 Study Team. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004. 5:203–211.

8. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernández-Viña MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001. 62:1009–1030.

9. Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, Chang SC. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother. 2007. 60:599–604.

10. Lee KW, Oh DH, Lee C. Allelic and haplotypic diversity of HLA-A,-B,-C,-DRB1, and -DQB1 genes in the Korean population. Tissue Antigens. 2005. 65:437–447.

11. Park WB, Choe PG, Song KH, Lee SW, Jang HC, Jeon JH, Park SW, Park MH, Oh MD, Choe KW. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis. 2009. 48:365–367.

12. The Korean Society for AIDS. Clinical guidelines for diagnosis and treatment of HIV/AIDS in HIV-infected Koreans. Infect Chemother. 2011. 43:89–128.